Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
Hyo Young Lee, Dae Won Jun, Hyun Jung Kim, Hyunwoo Oh, Waqar Khalid Saeed, Hyeongsik Ahn, Ramsey C. Cheung, Mindie H. Nguyen
Korean J Intern Med. 2019;34(2):296-304. Published online 2018 Mar 20 DOI: https://doi.org/10.3904/kjim.2017.194
Citations to this article as recorded by 
Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
Udita Gupta, Thomas Ruli, Danyaal Buttar, Mohamed Shoreibah, Meagan Gray
The American Journal of the Medical Sciences.2024; 367(2): 77. CrossRef
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui, Jinjun Guo
Frontiers in Endocrinology.2023;[Epub] CrossRef
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee
Biomedicine & Pharmacotherapy.2023; 161: 114445. CrossRef
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień
Medicina.2023; 59(10): 1789. CrossRef
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Jeongmin Lee, Seung-Hwan Lee
The Korean Journal of Internal Medicine.2023; 38(6): 797. CrossRef
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
World Journal of Hepatology.2022; 14(1): 119. CrossRef
Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial
Davide Noto, Salvatore Petta, Antonina Giammanco, Rossella Spina, Daniela Cabibbi, Rossana Porcasi, Rosalia Caldarella, Marcello Ciaccio, Roberto Muratore, Angelo B. Cefalù, Antonio Craxi, Maurizio Averna
Nutrition, Metabolism and Cardiovascular Diseases.2022; 32(5): 1288. CrossRef
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Anna Martin, Sonja Lang, Tobias Goeser, Münevver Demir, Hans-Michael Steffen, Philipp Kasper
Current Atherosclerosis Reports.2022; 24(7): 533. CrossRef
Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
Sang Hyun Seo, Da Hyun Lee, Yu Seol Lee, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Soo Han Bae, Seung Up Kim
Gastroenterology Report.2022;[Epub] CrossRef
A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
Mitra Ahadi, Kasra Molooghi, Negin Masoudifar, Ali Beheshti Namdar, Hassan Vossoughinia, Mohammadreza Farzanehfar
Journal of Gastroenterology and Hepatology.2021; 36(6): 1497. CrossRef
Association between toothbrushing and non-alcoholic fatty liver disease
Ji-Youn Kim, Yong-Moon Park, Gyu-Na Lee, Hyun Chul Song, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko, Houkai Li
PLOS ONE.2021; 16(5): e0243686. CrossRef
The Propensity of the Human Liver to Form Large Lipid Droplets Is Associated with PNPLA3 Polymorphism, Reduced INSIG1 and NPC1L1 Expression and Increased Fibrogenetic Capacity
Flaminia Ferri, Simone Carotti, Guido Carpino, Monica Mischitelli, Alfredo Cantafora, Antonio Molinaro, Maria Eva Argenziano, Simona Parisse, Alessandro Corsi, Mara Riminucci, Quirino Lai, Gianluca Mennini, Gustavo Spadetta, Francesco Pugliese, Massimo Ro
International Journal of Molecular Sciences.2021; 22(11): 6100. CrossRef
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Heng Li, Xiao-Hua Yu, Xiang Ou, Xin-Ping Ouyang, Chao-Ke Tang
Progress in Lipid Research.2021; 83: 101109. CrossRef
Pleiotropic effects of ezetimibe
I. I. Shaposhnik, V. V. Genkel
Kardiologiia.2020; 59(12S): 12. CrossRef
Nonalcoholic fatty liver disease
Vincent M. Vacca
Nursing.2020; 50(3): 32. CrossRef
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
Metabolism.2020; 111: 154299. CrossRef
Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases
Pooja Malhotra, Ravinder K. Gill, Seema Saksena, Waddah A. Alrefai
Frontiers in Medicine.2020;[Epub] CrossRef
The utility of ezetimibe therapy in nonalcoholic fatty liver disease
Baek Gyu Jun, Gab Jin Cheon
The Korean Journal of Internal Medicine.2019; 34(2): 284. CrossRef
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
Niki Katsiki, Dimitri P Mikhailidis, Maciej Banach
Expert Opinion on Pharmacotherapy.2019; 20(16): 2007. CrossRef
Lipids: a personal view of the past decade
Niki Katsiki, Dimitri P Mikhailidis
Hormones.2018; 17(4): 461. CrossRef
Soybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary Cholesterol
Janin Henkel, Eugenia Alfine, Juliana Saín, Korinna Jöhrens, Daniela Weber, José Castro, Jeannette König, Christin Stuhlmann, Madita Vahrenbrink, Wenke Jonas, André Kleinridders, Gerhard Püschel
Nutrients.2018; 10(9): 1326. CrossRef